Aandeel PV3B EYEPOINT PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Aandelen

PV3B

US30233G2093

Beurs gesloten - Deutsche Boerse AG
Andere beurzen
 15:29:02 10-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
8,28 EUR -2,43% Intraday-grafiek van EyePoint Pharmaceuticals, Inc. -14,55% -60,94%
04/06 EYEPOINT PHARMACEUTICALS, INC. : JPMorgan Chase geeft koopadvies ZM
08/05 EYEPOINT PHARMACEUTICALS, INC. : Baird bevestigt koopadvies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
EyePoint Pharmaceuticals : Investor Presentation May 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation
Sector Update: Health Care Stocks Gain Pre-Bell Monday
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board
EyePoint Pharmaceuticals : Investor Presentation March 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers EYPT
  4. Koers PV3B
  5. Nieuws EyePoint Pharmaceuticals, Inc.
  6. Andere talen